Overview of Opportunity

Despite advances of anti-VEGF treatment significant unmet medical need remains. While many patients achieve a good clinical outcome with anti-VEGF therapy, these initial results can deteriorate over time and a significant number of patients achieve sub-optimal BCVA with existing therapeutic agents.   


Based on extensive research at the Yale University School of Medicine, CavtherRx was formed to develop innovative caveolin modulators, which have been shown to work on multiple critical components of pathological angiogenesis.  By addressing multiple factors responsible for vision loss caused by vascular permeability, inflammation and angiogenesis, we are working to provide more durable and widespread therapeutic benefits to patients.